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Background
Tumor-derived autophagosomes, DRibbles, are DC-
targeted microvesicles containing more than 100 putative
NSCLC antigens, many as potential altered-peptide ligands
(APL), which could increase their immunogenicity. The
microvesicles also contain at least 15 DAMPs with agonist
activity for TLR 2, 3, 4, 7 and 9. In preclinical models
DRibble immunotherapy provided significant cross-pro-
tection against 8 of 9 tumors and was effective in treating
established tumors. We hypothesize that the efficacy of
DRibbles’ vaccination stems from their ability to present
stabilized tumor-derived short-lived proteins (SLiPs) and
defective ribosomal products (DRiPs) that are normally
not processed and presented by professional antigen pre-
senting cells (APCs). These SLiPs and DRiPs represent a
potential pool of tumor antigens against which the host is
not tolerant. The DPV-001 vaccine is made up of DRibbles
produced from two cell lines, UbiLT3 and UbiLT6. The
priming vaccination includes DRibbles from both cell
lines, while subsequent administrations alternate between
DRibbles derived from the two cell lines.
Methods and results
Patients are vaccinated at 3-week intervals, alone or with
assigned adjuvant (GM-CSF or imiquimod), for a total
of 7 doses, and an option to continue vaccinating at
6 week intervals (without adjuvant). PBMCs and serum
are collected at baseline and at each vaccination.
Immune monitoring panels are run on peripheral whole
blood to evaluate lymphocyte populations and their acti-
vation status. PBMCs from the baseline visit and week
12/13 are stimulated with DRibbles (vaccine and con-
trol) to measure vaccine-specific cytokine production.
Patient serum from the baseline visit and week 12/13 is
analyzed for antibody response to >9000 human pro-
teins using ProtoArrays. Whole exome sequencing of
tumors and normal tissue is performed when possible to
evaluate antibody responses to mutations and altered
peptide ligands. Nanostring and multispectral IHC are
being used to evaluate tumor immune biomarkers when
tissue is available.
Conclusions
The DPV-001 vaccine provides a source of broad-spec-
trum relevant antigens. Preliminary analyses of patients
receiving the DPV-001 vaccine show effects on T cells
and B cells with increased antibody responses at 12 or
13 weeks.
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